Compare Regeneron Pharmaceuticals Inc (REGN) vs Cactus Inc. Class A Common Stock (WHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Cactus Inc. Class A Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $795.5 (market cap $80.14B), while Cactus Inc. Class A Common Stock trades at $62.37 (market cap $5.02B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 16× Cactus Inc. Class A Common Stock's market cap, and Cactus Inc. Class A Common Stock pays the higher dividend (0.96%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Cactus Inc. Class A Common Stock for 0 Days on average.
| REGN | WHD | |
|---|---|---|
Market Cap | $80.14B | $5.02B |
Volume | 878,669 | 804,573 |
Sector | Health | Energy |
52-Week High | $852.03 | $73.73 |
52-Week Low | $569.17 | $35.26 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $74.85B | $4.71B |
Dividend Yield | 0.48% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $753.12, down 1.27% on the day, with a bullish technical signal supported by moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 19.26, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent positive news includes a strategic expansion of its immunology alliance with Sanofi, valued up to $8 billion, and promising clinical trial data for oncology and muscle preservation therapies.
The outlook for REGN remains positive, driven by robust profitability, strategic partnerships, and a strong pipeline. Key risks include competitive pressures in the biopharma sector and reliance on key products like Eylea. With a consensus price target of $856.25 and no sell ratings from analysts, the stock presents a compelling opportunity for growth-oriented investors, though market volatility and regulatory developments warrant monitoring.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Cactus Inc. Class A Common Stock
Cactus Inc. designs, manufactures, and rents wellhead and pressure control equipment for oil and gas drilling, completion, and production, operating under the Cactus Wellhead brand.
Read more on WHD →
